Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | [225]Ac-FL-020 |
| Synonyms | |
| Therapy Description |
[225]Ac-FL-020 is a radioconjugate that contains the alpha-radiation emitting radionuclide actinium-225 and targets PSMA, which potentially induces apoptosis and inhibits growth of PSMA-expressing tumors (Cancer Res (2024) 84 (6_Supplement): 6023). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| [225]Ac-FL-020 | 225Ac-FL-020 | [225]Ac-FL-020 is a radioconjugate that contains the alpha-radiation emitting radionuclide actinium-225 and targets PSMA, which potentially induces apoptosis and inhibits growth of PSMA-expressing tumors (Cancer Res (2024) 84 (6_Supplement): 6023). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06492122 | Phase I | [225]Ac-FL-020 | Study With [225Ac]Ac-FL-020 in mCRPC Participants (ProTACT) | Recruiting | USA | TUR | AUS | 0 |